
# The Inextricable Link: Service-Academic Partnership for the Public's Health

Gabriel M Leung



#### Agenda

- Grand ChallengesLost in Translation?
- Health Protection
- Health Improvement
- Health Services and Systems











#### Grand Challenges – Lost in Translation?




#### Grand Challenge 1 in Clinical Science

- How could one best translate research (especially in basic science) into clinical practice?
  - A question of multi-directional technology transfer between:
    - laboratory and bedside → improved health



#### Grand Challenge 2 in Clinical Science

- Also a question of multi-directional technology transfer between:
  - academia and industry → improved wealth
- Emphasis of value creation from the production of knowledge through research
- Facilitated over the years by:
  - legislation Bayh-Dole Act (1984) in US and Allègre Innovation Laws (1999) in France, giving institutions performing publicly funded research IP rights, thus potential financial gains
  - commercial arms of research bodies MRC Technology Co., INSERM Transfert, NIH Roadmap-Clinical and Translational Science Awards
  - funding public, pharma and venture capital
- Whither Hong Kong, China and indeed much of Asia?
- How should we incentivise innovation?



### Parallel Grand Challenge in *Translational Public Health*

- Little good comes of best, current evidence unless it is translated into public health policy, and the interventions then implemented expeditiously and effectively
- "Struggles with human behaviour and organisational inertia, infrastructure and resource constraints, and the messiness of proving the effectiveness of 'moving targets' under conditions that investigators cannot fully control"
- "Mastery of the 'implementation science' of fielding and evaluating interventions in real world settings and of the disciplines that inform the design of those interventions, such as clinical epidemiology and evidence synthesis, communication theory, behavioral science, public policy, financing, organizational theory, system redesign, informatics, and mixed methods/qualitative research"

JAMA 2008:299:211-3

#### Grand Challenge in Translational Public Health

- Prerequisite: playing matchmaker between government and academics
- TRIP (Translating Research into Practice) grants from AHRQ in US; Studies in Health Services by HHSRF; Public Policy Research by RGC; some RFCID commissioned grants
  - however the invested amounts pale in comparison to those devoted to the clinical science grand challenges
  - "Disproportion has consequences, and the current policy of spending 1.5% (US) or 3.4% (HK) of (biomedical) research dollars on health services research is probably costing lives" (JAMA 2008;299:221-3; UGC/RGC, RFCID and HHSRF statistics)

### Are there examples of translational public health in action locally?

Health Protection

• Health Improvement




• Health Services and Systems





## Health Protection – standing on guard for thee



















## Symptomatic attack rates could be reduced substantially by these interventions

	Symptomatic attack rate	Peak prevalence of quarantine	Peak prevalence of isolation	Anti-viral doses required
Baseline (no intervention)	49%	-	1.4%	0.9
Quarantine	33%	9.8%	0.6%	0.6
Quarantine and isolation	29%	7.3%	0.9%	1.2
Quarantine and anti-virals	29%	8.2%	0.5%	3.9
Quarantine, isolation and antivirals	27%	6.4%	0.8%	3.9
Quarantine, isolation, anti-virals and contact tracing	23%	14.0%	0.6%	9.9





#### **Cervical Cancer Prevention**

- Comparator of status quo
  - Does Cervical Screening Programme
    Department of Holith
    Department of H
    - process measures (average and distribution of coverage)
  - Will it work?
    - modelling (2 different approaches)
    - cytology or HPV testing; and in what order?
- Marginal economic analysis
  - What does \_\_\_\_\_\_ add, in terms of QALYs?
  - At what cost? Who should pay?
  - Is it acceptable to girls (boys), parents and the general public?

### Health Improvement – adding years to life, and life to years





#### Children of 1997 - the study

All births in Hong Kong in April and May 1997

- 1. 8327 infants participated, recruited through all MCHCs
- 2. Interviewed at 3, 9 and 18 months



Collaboration between

- 1. The University of Hong Kong
- 2. Department of Health



Designed to answer many, many questions


- 1. Smoking (in utero & postpartum)
- 2. Breastfeeding
- 3. Method of delivery
- ...& health care use



#### The "Marlboro" (not Mozart) effect



#### Infant SHS exposure before and after birth among non-smoking mothers (95.4% of sample)





#### Health and Economic Consequences

 Table 3
 Costs of health services utilisation in the first year of life attributable to ETS exposure during pregnancy for the

 1997 annual birth cohort

		Adjusted	OR*	PAR (%)		- Extra number of	Total extra	Relative contribution to the cost (%)	
	Crude OR	Point estimate	95% CI	Point estimate	95% CI	episodes attributable to ETS	cost (US\$1000)	Private sector	Public sector
Consultation									
Respiratory/fever	1.20	1.19	(1.08 to 1.31)	6.0	(2.6 to 9.4)	10274	273	89.2	10.8
Any illness Hospitalisation	1.28	1.26	(1.14 to 1.39)	7.7	(4.3 to 10.9)	16192	437	87.3	12.7
Respiratory/fever	1.14	1.11	(0.98 to 1.27)	5.7	(-1.3 to 12.2)	N/A	N/A	N/A	N/A
Any illness	1.20	1.18	(1.05 to 1.31)	7.4	(2.3 to 12.2)	1581	2142	18.3	81. <i>7</i>

OR, odds ratio; CI, confidence interval; PAR, population attributable risk.

N/A denotes items not calculated because the associated PARs did not achieve statistical significance at the 0.05 level.

\*Odds ratios are adjusted for maternal education level, maternal full time employment, maternal age, birth order, method of delivery, birth weight, and breast feeding.

- The cost of inpatient and outpatient care (excluding preventive care episodes) for an annual cohort of infants in the first year of life attributable to SHS is conservatively estimated to be >HK\$30M
- This is about 10% of the total cost of direct medical care for these infants



#### Moderating effect of smoking hygiene

	D	Respiratory Tract or Febrile Illness			Any Illness			
Smoking Category	Proportion Exposed to Each Smoking Category, %	Proportion Ever Hospitalized, %		P Value for Linear Trend	Proportion Ever Hospitalized, %		P Value for Linea Trend	
n utero								
Maternal smoking or secondhand smoke exposure during pregnancy†								
No	33.2	16.7	1 (NA)	.05	26.0	1 (NA)	.008	
Exposure to secondhand smoke	62.2	18.8	1.09 (0.95-1.25)		29.6	1.15 (1.02-1.29)		
Active smoking	4.6	23.8	1.37 (1.02-1.84)		34.6	1.33 (1.02-1.73)		
P value		.003	,		<.001	,		
After birth								
Maternal smoking‡								
No	97.2	18.2	1 (NA)	.35	28.6	1 (NA)	.63	
Yes, but not within 3 m	2.2	21.1	1.11 (0.75-1.64)		30.1	1.00 (0.71-1.42)		
Yes, within 3 m	0.6	28.9	1.33 (0.67-2.63)		40.0	1.23 (0.66-2.29)		
P value		.12	,		.22	,		
Paternal smoking§								
No	66.6	17.4	1 (NA)	.13	27.4	1 (NA)	.19	
Yes, but not within 3 m	26.3	19.2	1.01 (0.87-1.17)		29.8	0.99 (0.87-1.12)	1.12	
Yes, within 3 m	7.1	23.9	1.28 (1.01-1.61)		35.7	1.23 (1.00-1.51)		
P value		<.001			<.001	(,		
Other smokers at home!								
No	84.8	17.8	1 (NA)	.14	27.8	1 (NA)	.04	
Yes, but not within 3 m	10.9	20.5	1.06 (0.88-1.29)		32.5	1.12 (0.95-1.32)		
Yes, within 3 m	4.4	23.2	1.22 (0.93-1.61)		35.2	1.22 (0.95-1.56)		
P value		.01	,,		<.001	,,		
Any smoker at home¶								
No	58.8	17.2	1 (NA)	.07	27.1	1 (NA)	.03	
Yes, but not within 3 m	30.8	18.9	0.99 (0.86-1.15)		29.5	1.00 (0.88-1.13)	ſ	
Yes, within 3 m	10.4	23.2	1.27 (1.04-1.55)		35.4	1.28 (1.07-1.52)		
P value		<.001	,,		<.001	,		



#### Policy implications

- Broadens the issue from solely maternal smoking in pregnancy to that of the whole household
- Directly informed the debate on 2007 enactment of the Smoking (Public Health) Ordinance
- Suggests that targeted smoking cessation programmes for fathers and other family members during pregnancy may be useful (vide Sophia Chan's work)
- Smoking hygiene can be a possible harm reduction interim measure







#### Controversy, Confusion and Obfuscation...

News headlines

The New Hork Times Some Extra Heft

May Be Helpful, New Study Says

#### Some Unexpected Findings

People who are overweight but not obese have a lower risk of death than those at a normal weight, according to a new study. Those who are very thin or obese, however, are at a higher risk of death.










Food industry-supported pressure group infomercials


**Obesity:** 



ConsumerFreedom.com



Life time thin person



20yrs 30yrs 40yrs 50yrs 60yrs 70yrs 80yrs

Thin, gets fat, gets ills at 50, loses weight from illness













Person with more fat at age 40 has fewer years of life to live

Both people are equally fat at age 60, but different length of life ahead, so being fat at 60 appears unrelated to


At age 70, the person who is currently thinner has a shorter remaining lifespan, so being fat at 70 appears protective

Do changes in weight and body composition due to ill-health at older ages bias these comparisons?





## Physical activity in healthy and unhealthy older people



\* Inactive people compared with physically active people with the same number of health problems


#### **Public Health Implications**

- Research suggesting that fatness is not a risk factor and that physical activity does not matter for mortality is biased
- Obesity and inactivity c(w)ould become an overwhelming public health problem in China
- Interventions to prevent obesity at all ages are needed now
- BMI (weight and height) alone is an imperfect measure of health risk, and should be supplemented by waist circumference, waist-hip ratio, % body fat, especially in older adults. EHS has already started to measure some of these routinely.



# Health Services and Systems – somewhere over rainbow... (perhaps) lies the promised land





#### Thank You...(in order of appearance)

- Research collaborators: Steven Riley (JE), Joe Wu (PanFlu), Ben Cowling (NPI), Pauline Woo (HPV), TH Lam ("Children of 1997"), Mary Schooling (EHS cohort), Keith Tin (health financing)
- Sponsors: RFCID (commissioned projects and investigator-initiated grants), US CDC, HHSRF, FHB
- Translational partners: CHP; HA; EHS, DH; FHB

To us, knowledge, how good and lovely soever it be for its own sake, must always be a by-end, a step merely towards the still better and lovelier goal of "good-will towards men."

Our object, then, in reviewing these researchers, and in adding to them such observations as our own sphere of action supplies, should be to deduce from them rules of practice, to gather from the tree of knowledge fruit for the solace and refreshment of mankind.

Thomas King Chambers Goulstonian Lecture, RCP, 1850